Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology
Volume 18, Issue 5, Pages 321-326
Brief Communication

Mycophenolate Mofetil for the Treatment of Autoimmune Hepatitis in Patients Refractory to Standard Therapy

Shane M Devlin, Mark G Swain, Stefan J Urbanski, and Kelly W Burak

1Liver Unit, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
2Department of Pathology, University of Calgary, Calgary, Alberta, Canada

Received 21 January 2004; Accepted 5 March 2004

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


There are limited therapeutic options available for patients with autoimmune hepatitis in whom conventional treatment fails. A case series of five patients unresponsive to or unable to take azathioprine, 6-mercaptopurine or corticosteroids who were treated with mycophenolate mofetil (MMF) is reported. While on MMF, alanine aminotransferase normalized or remained normal in all patients. MMF had a steroid-sparing effect and histological remission was demonstrated in one patient after seven months of MMF. One patient experienced an uncomplicated episode of pyelonephritis. In conclusion, MMF can effectively induce and maintain remission in refractory autoimmune hepatitis patients.